

## NOTICE REQUIRED UNDER ASX LISTING RULE 3.13.1

---

Bio-Gene Technology Limited (ASX: BGT, 'Bio-Gene' or the 'Company') advises that it currently intends to hold its 2023 Annual General Meeting on Thursday, 23 November 2023 at 11am. Accordingly, it advises for the purposes of ASX Listing Rule 3.13.1 that the closing date for receipt of nominations of directors is 6 October 2023.

Approved for release by the Board of Directors.

- ENDS -

### For further information, please contact:

Bio-Gene Technology Limited:

Tim Grogan, CEO

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

M: 0438 655 452

Rod Valencia, CFO

E: [bgt.info@bio-gene.com.au](mailto:bgt.info@bio-gene.com.au)

M: 0450 218 832

Media & Investor Relations:

Adrian Mulcahy, Investor Relations

E: [adrian.mulcahy@automicgroup.com.au](mailto:adrian.mulcahy@automicgroup.com.au)

M: 0438 630 422

Tristan Everett, Media Relations

E: [tristan.everett@automicgroup.com.au](mailto:tristan.everett@automicgroup.com.au)

M: 0403 789 096

### About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Bio-Gene's novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.